The primary objective of this clinical trial is to determine if treatment with Butyrate
formulation that consists of butyric acid as calcium and magnesium derivatives (Ca-Mg
Butyrate) improves the physical function of men and women Veterans suffering from Gulf War
Illness (GWI). The primary outcome measure is a change from baseline on the Short Form Health
Survey 36-item (VSF-36), with respect to physical functioning and symptoms. The secondary
outcome will focus on the drug's role in (a) restoring gut microbiome and virome, (b)
decreasing gastrointestinal disturbances (constipation, diarrhea, pain), (c) decreasing
chronic fatigue, (d) decreasing systemic inflammation, and (e) a decrease in cognitive
deficits.
Phase:
Phase 2
Details
Lead Sponsor:
VA Office of Research and Development
Collaborators:
Miami VA Healthcare System VA Salt Lake City Health Care System